Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 19/20 | 0.68 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 2/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.41 |
| ▸ | PAK4 | O96013 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.41 |
| ▸ | CDK8 | P49336 | 2/20 | 0.41 |
| ▸ | CLK2 | P49760 | 2/20 | 0.41 |
| ▸ | CDK7 | P50613 | 2/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | PRKX | P51817 | 2/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | MELK | Q14680 | 2/20 | 0.41 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.41 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2727995 | 1.00 | ROCK2 (0.68) | ROCK2PRKAA2CDC7DAPK3PAK4 | |
| SCHEMBL2710647 | 0.92 | ROCK2 (0.67) | ROCK2PRKAA2CDC7DAPK3PAK4 | |
| SCHEMBL13387778 | 0.92 | ROCK2 (0.67) | ROCK2PRKAA2CDC7DAPK3PAK4 | |
| SCHEMBL2725767 | 0.90 | ROCK2 (0.58) | ROCK2 | |
| SCHEMBL2725762 | 0.90 | ROCK2 (0.58) | ROCK2 | |
| SCHEMBL2728611 | 0.90 | ROCK2 (0.58) | ROCK2 | |
| SCHEMBL2726225 | 0.90 | ROCK2 (0.54) | ROCK2PRKAA2CDC7DAPK3PAK4 | |
| SCHEMBL2729740 | 0.90 | ROCK2 (0.55) | ROCK2PRKAA2CDC7DAPK3PAK4 | |
| SCHEMBL2713303 | 0.89 | ROCK2 (0.69) | ROCK2 | |
| SCHEMBL13387457 | 0.89 | ROCK2 (0.69) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630144-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-09-07 | — | — | EP | disclosed |
| EP-2630144-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-09-07 | — | — | EP | disclosed |
| US-9000154-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-9000154-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| EP-2630144-A1 | RHO KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-08-28 | — | — | EP | disclosed |
| US-20120270868-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270868-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| WO-2012054367-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012054367-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270868-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, RHOA | ROCK2 2/4885PRKAA2 372/4885CDC7 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.